Skip to main content
Cancer Medicine logoLink to Cancer Medicine
. 2019 May 8;8(7):3592–3603. doi: 10.1002/cam4.2209

Interethnic differences in pancreatic cancer incidence and risk factors: The Multiethnic Cohort

Brian Z Huang 1,2, Daniel O Stram 3, Loic Le Marchand 4, Christopher A Haiman 3,5, Lynne R Wilkens 4, Stephen J Pandol 6, Zuo‐Feng Zhang 1, Kristine R Monroe 3, Veronica Wendy Setiawan 3,5,
PMCID: PMC6601579  PMID: 31066497

Abstract

While disparity in pancreatic cancer incidence between blacks and whites has been observed, few studies have examined disparity in other ethnic minorities. We evaluated variations in pancreatic cancer incidence and assessed the extent to which known risk factors account for differences in pancreatic cancer risk among African Americans, Native Hawaiians, Japanese Americans, Latino Americans, and European Americans in the Multiethnic Cohort Study. Risk factor data were obtained from the baseline questionnaire. Cox regression was used to estimate the relative risks (RRs) and 95% confidence intervals (CIs) for pancreatic cancer associated with risk factors and ethnicity. During an average 16.9‐year follow‐up, 1,532 incident pancreatic cancer cases were identified among 184,559 at‐risk participants. Family history of pancreatic cancer (RR 1.97, 95% CI 1.50‐2.58), diabetes (RR 1.32, 95% CI 1.14‐1.54), body mass index ≥30 kg/m2 (RR 1.25, 95% CI 1.08‐1.46), current smoking (<20 pack‐years RR 1.43, 95% CI 1.19‐1.73; ≥20 pack‐years RR 1.76, 95% CI 1.46‐2.12), and red meat intake (RR 1.17, 95% CI 1.00‐1.36) were associated with pancreatic cancer. After adjustment for these risk factors, Native Hawaiians (RR 1.60, 95% CI 1.30‐1.98), Japanese Americans (RR 1.33, 95% CI 1.15‐1.54), and African Americans (RR 1.20, 95% CI 1.01‐1.42), but not Latino Americans (RR 0.90, 95% CI 0.76‐1.07), had a higher risk of pancreatic cancer compared to European Americans. Interethnic differences in pancreatic cancer risk are not fully explained by differences in the distribution of known risk factors. The greater risks in Native Hawaiians and Japanese Americans are new findings and elucidating the causes of these high rates may improve our understanding and prevention of pancreatic cancer.

Keywords: cohort, epidemiology, ethnicity, incidence, minority, pancreatic cancer

1. INTRODUCTION

Pancreatic cancer is one of the deadliest malignancies in the United States. It has a 5‐year survival rate of only 8% and is the third most common cancer‐related death among men and women.1 By 2030, pancreatic cancer is estimated to surpass colorectal cancer to become the second leading cause of cancer mortality.2 Given these circumstances, a better understanding of its risk factors is imperative for preventing pancreatic cancer occurrence.

Ethnic differences in pancreatic cancer incidence have been investigated in several previous settings.3 Most prior literature has focused on the higher rates of pancreatic cancer in African Americans compared to whites,4, 5 with some research suggesting that this disparity may be partially explained by the greater prevalence of smoking, diabetes, and obesity among African Americans.4, 6 However, only a few studies have assessed other ethnic minorities, which have observed that Hispanics and Asians/Pacific Islanders have lower incidence rates of pancreatic cancer compared to whites and African Americans.7, 8 Additionally, no previous study has closely evaluated the relationships between known risk factors and pancreatic cancer across multiple ethnic minorities. Thus, there is limited information as to whether risk factors identified in past literature explain varying degrees of pancreatic cancer incidence between racial/ethnic subpopulations.

The purpose of this study was to investigate differences in pancreatic cancer incidence across African Americans, Native Hawaiians, Japanese Americans, Latino Americans, and European Americans in the Multiethnic Cohort (MEC). In particular, we sought to assess the extent to which known risk factors account for these potential differences and whether the influence of specific risk factors varies by race/ethnicity. Understanding these differences may allow us to better elucidate pancreatic cancer etiology across ethnic groups and establish more targeted prevention strategies.

2. METHODS

2.1. Study population

The MEC was established in 1993‐1996 to investigate cancer etiology. It is comprised of >215,000 participants aged 45‐75 at entry recruited from Los Angeles County and Hawaii. The five main ethnic groups are European American, African American, Latino American, Japanese American, and Native Hawaiian.9 All participants completed a self‐administered baseline questionnaire, which included information on demographics, medical conditions, family history of cancer, and lifestyle factors. Individuals were excluded from this study if they were not in the five main race/ethnicity groups (n = 13,987), had a prior pancreatic cancer diagnosis (n = 56), or were missing information on diet, diabetes, body mass index (BMI), and smoking (n = 12,957). Smokers with missing pack‐years data were further excluded (n = 4,091).

2.2. Exposure assessment

Exposure information was obtained from the baseline questionnaire. Participants were asked to self‐report their race/ethnicity, height, weight, diabetes history, family history of cancer (first‐degree relative), and frequency and duration of cigarette smoking. Smoking was evaluated as overall status (never, past, current) and with pack‐year information (never, past with <20 pack‐years, past with ≥20 pack‐years, current with <20 pack‐years, current with ≥20 pack‐years). Height and weight measurements were used to calculate BMI (kg/m2). Alcohol use (g/day) and red meat (processed and nonprocessed) intake (g/kcal/day) in the year prior to cohort entry were assessed through a food frequency questionnaire validated for a multiethnic population.10

2.3. Outcome

Participants were followed from cohort entry to pancreatic cancer diagnosis, death, or end of follow‐up (31 December 2013). Annual linkages with the statewide Surveillance, Epidemiology and End Results (SEER) registries of Hawaii and California were used to identify incident cases of pancreatic cancer (ICD‐O‐3 codes C25.0‐C29.9). Death dates for right‐censoring were ascertained using linkages with death certificate files for Hawaii and California and the National Death Index.

2.4. Statistical analyses

Pancreatic cancer incidence rates, left truncated at age 45 and age‐standardized using the United States 2000 standard population, were calculated for each race/ethnicity group. Race/ethnicity‐specific incidence rates were compared to the incidence rates for European Americans by testing the standardized rate ratios. Cox models with time since cohort entry as the time metric were used to assess the influence of race/ethnicity and risk factors on pancreatic cancer incidence. Minimally adjusted models, with age and sex as strata variables and race/ethnicity as a covariate, were fitted for each exposure. We also ran fully adjusted models which included age and sex as strata variables and race/ethnicity, family history of pancreatic cancer, diabetes, BMI (<25, 25‐30, ≥30 kg/m2), smoking with pack‐year information (never, past with <20 pack‐years, past with ≥20 pack‐years, current with <20 pack‐years, current with ≥20 pack‐years), alcohol use (none, <24, 24‐48, >48 g/day), and red meat intake (examined as quartiles) as covariates. Trends were examined using a model that treated the exposure as a continuous variable coded as consecutive numbers (eg, 1, 2, 3). To account for potential residual confounding by smoking, we ran models incorporating more detailed smoking variables,11 including current status, number of cigarettes smoked, smoking duration, and time since quitting. As this further adjustment did not change the results, only the results from the original models are presented. Race/ethnicity‐stratified analyses were performed to evaluate the relationships between risk factors and pancreatic cancer in each subpopulation. Tests of heterogeneity were conducted using models with cross‐product terms for each risk factor and race/ethnicity.

Population attributable fractions (PAF) were calculated for risk factors positively associated with pancreatic cancer using the method developed for cohort studies.12 This method calculates the PAF and 95% confidence intervals for various risk behavior modifications across specified follow‐up time intervals, while accounting for other risk factors and mortality as a competing risk. We calculated the PAFs associated with modifications in risk factors including BMI (≥25 to <25, ≥30 to <25 kg/m2), smoking (current to never), diabetes (yes to no), and red meat intake (second/third/fourth quartiles to first quartile). We also calculated PAFs for all of the aforementioned risk factors combined. Population attributable fractions were calculated for the entire cohort as well as for each racial/ethnic group over a 20‐year follow‐up period.

Schoenfeld residuals were used to verify the proportional hazards assumption and Martingale and deviance residuals were assessed to determine model fit.13 Analyses were conducted using SAS 9.3 (Cary, NC) and reported P‐values are two‐sided.

3. RESULTS

This study consisted of 184,559 at‐risk individuals (100,969 females and 83,590 males). The largest racial/ethnic group was Japanese Americans (29.0%), followed by European Americans (25.1%), Latino Americans (22.0%), African Americans (16.7%), and Native Hawaiians (7.3%). The average age at cohort entry was 59.9 (standard deviation 8.8). Approximately half of the participants were nonsmokers (44.9%) and non‐alcohol users (51.2%), while nearly 60% of the cohort was either overweight or obese. In addition, 11.7% of participants had diabetes while only 1.7% had a family history of pancreatic cancer (Table 1).

Table 1.

Baseline characteristics of Multiethnic Cohort Study participants from 1993 to 2013

Characteristic Total (N = 184,559) European American (N = 46,356) African American (N = 30,731) Native Hawaiian (N = 13,412) Japanese American (N = 53,429) Latino American (N = 40,631)
N % N % N % N % N % N %
Age at baseline (y)a 59.9 (8.8) 58.9 (9.1) 61.0 (9.0) 56.4 (8.6) 61.0 (9.1) 59.7 (7.8)
Age group at baseline
<50 31,095 16.9 9,454 20.4 4,452 14.5 3,791 28.3 8,438 15.8 4,960 12.2
50‐54 27,673 15.0 7,938 17.1 4,283 13.9 2,683 20.0 7,040 13.2 5,729 14.1
55‐59 29,370 15.9 6,985 15.1 4,548 14.8 2,110 15.7 6,794 12.7 8,933 22.0
60‐64 31,744 17.2 7,144 15.4 4,296 14.0 1,961 14.6 8,892 16.6 9,451 23.3
65‐69 32,409 17.6 7,190 15.5 6,366 20.7 1,601 11.9 10,614 19.9 6,638 16.3
≥70 32,268 17.5 7,645 16.5 6,786 22.1 1,266 9.4 11,651 21.8 4,920 12.1
Sex
Male 83,590 45.3 21,434 46.2 11,235 36.6 5,883 43.9 25,336 47.4 19,702 48.5
Female 100,969 54.7 24,922 53.8 19,496 63.4 7,529 56.1 28,093 52.6 20,929 51.5
Family history of pancreatic cancer 3,175 1.7 800 1.7 357 1.2 197 1.5 1,250 2.3 571 1.4
Diabetes 21,563 11.7 2,741 5.9 4,822 15.7 1,988 14.8 5,626 10.5 6,386 15.7
Body mass index (kg/m2)
<25 76,973 41.7 21,356 46.1 8,295 27.0 3,578 26.7 32,208 60.3 11,536 28.4
25‐30 70,865 38.4 16,854 36.4 12,580 40.9 5,037 37.6 17,471 32.7 18,923 46.6
≥30 36,721 19.9 8,146 17.6 9,856 32.1 4,797 35.8 3,750 7.0 10,172 25.0
Smoking status
Never 82,852 44.9 18,229 39.3 11,910 38.8 5,305 39.6 26,991 50.5 20,417 50.2
Past 72,086 39.1 20,499 44.2 11,907 38.8 5,082 37.9 20,152 37.7 14,446 35.6
Current 29,621 16.1 7,628 16.5 6,914 22.5 3,025 22.6 6,286 11.8 5,768 14.2
Pack‐yearsa 10.2 (15.0) 13.5 (17.6) 10.0 (13.4) 12.2 (15.8) 9.8 (14.8) 6.4 (11.5)
Smoking status, with pack‐year information
Never 82,852 44.9 18,229 39.3 11,910 38.8 5,305 39.6 26,991 50.5 20,417 50.3
Past <20 pack‐years 53,370 28.9 13,702 29.6 9,431 30.7 3,648 27.2 14,253 26.7 12,336 30.4
Past ≥20 pack‐years 18,716 10.1 6,797 14.7 2,476 8.1 1,434 10.7 5,899 11.0 2,110 5.2
Current <20 pack‐years 15,960 8.7 2,778 6.0 4,528 14.7 1,556 11.6 3,006 5.6 4,092 10.1
Current ≥20 pack‐years 13,661 7.4 4,850 10.5 2,386 7.8 1,469 11.0 3,280 6.1 1,676 4.1
Alcohol use (g/day)
None 94,446 51.2 16,124 34.8 17,187 55.9 7,197 53.7 33,280 62.3 20,658 50.8
<24 69,009 37.4 21,379 46.1 10,858 35.3 4,731 35.3 15,715 29.4 16,326 40.2
24‐48 13,158 7.1 5,573 12.0 1,539 5.0 912 6.8 3,015 5.6 2,119 5.2
>48 7,946 4.3 3,280 7.1 1,147 3.7 572 4.3 1,419 2.7 1,528 3.8
Red meat intake (g/kcal/day)
Q1 (0‐14.1) 46,140 25.0 14,903 32.1 7,681 25.0 2,181 16.3 13,051 24.4 8,324 20.5
Q2 (14.1‐23.9) 46,139 25.0 12,038 26.0 7,186 23.4 3,061 22.8 14,335 26.8 9,519 23.4
Q3 (23.9‐35.2) 46,140 25.0 10,428 22.5 7,282 23.7 3,809 28.4 14,350 26.9 10,271 25.3
Q4 (35.2‐216.5) 46,140 25.0 8,987 19.4 8,582 27.9 4,361 32.5 11,693 21.9 12,517 30.8
Education
≤12 y 79,978 43.3 12,149 26.2 12,312 40.1 7,034 52.5 21,173 39.6 27,310 67.2
Some college/vocational 54,499 29.5 14,584 31.5 11,363 37.0 4,000 29.8 15,781 29.5 8,771 21.6
College graduate 49,311 26.7 19,537 42.1 6,919 22.5 2,344 17.5 16,344 30.6 4,167 10.3
Missing 771 0.4 86 0.2 137 0.5 34 0.3 131 0.3 383 0.9

All tests comparing distribution of risk factors across race/ethnicity groups had P < 0.0001.

a

Mean (standard deviation).

The prevalence of risk factors differed across racial/ethnic groups. Family history of pancreatic cancer was slightly more prevalent in Japanese Americans (2.3%) compared to the other subpopulations. Diabetes was less common in European Americans (5.9%) and more common in Japanese Americans (10.5%), Native Hawaiians (14.8%), African Americans (15.7%), and Latino Americans (15.7%). African Americans, Native Hawaiians, and Latino Americans were more likely to have BMI ≥25 kg/m2. Current smoking was more prevalent in Native Hawaiians (22.6%) and African Americans (22.5%), and less prevalent among Japanese Americans (11.8%) and Latino Americans (14.2%). Alcohol use was more commonly observed in European Americans (65.2%), while red meat intake (highest quartile) was greater among African Americans (27.9%), Latino Americans (30.8%), and Native Hawaiians (32.5%) (Table 1).

There were 1,532 incident cases of pancreatic cancer over an average follow‐up period of 16.9 years. Age‐standardized pancreatic cancer incidence rates were lowest in European Americans and highest in Native Hawaiians. Compared to European Americans (41.3 per 100,000 person‐years), Native Hawaiians (73.4), Japanese Americans (56.8), and African Americans (52.7) all had higher rates (P < 0.01). There was no difference in the incidence rates between Latino Americans (42.0) and European Americans (P = 0.87) (Table 2).

Table 2.

Age‐adjusted incidence rates of pancreatic cancer, by race/ethnicity

Race/ethnicity N Cases Person‐years Age‐adjusted incidence ratea P b
European American 46,356 306 784,877.9 41.3  
African American 30,731 277 488,746.5 52.7 <0.01
Native Hawaiian 13,412 128 221,361.6 73.4 <0.001
Japanese American 53,429 545 922,177.0 56.8 <0.0001
Latino American 40,631 276 697,674.8 42.0 0.87
a

Incidence rate per 100,000 person‐years, age‐standardized to US Census 2000 standard population, left truncated at age 45.

b

From a test comparing incidence rates to European Americans based on standardized rate ratios.

We also detected an increased risk of pancreatic cancer for Native Hawaiians, Japanese Americans, and African Americans in our Cox models (Table 3). When only adjusting for age and sex, Native Hawaiians (RR 1.75, 95% CI 1.42‐2.15), Japanese Americans (RR 1.32, 95% CI 1.15‐1.52), and African Americans (RR 1.34, 95% CI 1.13‐1.57) were all at greater risk for pancreatic cancer compared to European Americans. These risks remained elevated after adjusting for family history of pancreatic cancer, diabetes, BMI, smoking, alcohol, and red meat intake. Native Hawaiians had a 60% increased risk (RR 1.60, 95% CI 1.30‐1.98), Japanese Americans had a 33% increased risk (RR 1.33, 95% CI 1.15‐1.54), and African Americans had a 20% increased risk (RR 1.20, 95% CI 1.01‐1.42) compared to European Americans (Table 3). Native Hawaiians also had a higher risk compared to African Americans (P = 0.01), but not compared to Japanese Americans (P = 0.06). The risks for Japanese Americans and African Americans were not different from each other (P = 0.21).

Table 3.

Associations of race/ethnicity and various risk factors and pancreatic cancer risk

Risk factor Cases Person‐years Minimally adjusteda
RR (95% CI)
Fully adjustedb
RR (95% CI)
Race/ethnicity
European American 306 784,877.9 1 (ref) 1 (ref)
African American 277 488,746.5 1.34 (1.13‐1.57) 1.20 (1.01‐1.42)
Native Hawaiian 128 221,361.6 1.75 (1.42‐2.15) 1.60 (1.30‐1.98)
Japanese American 545 922,177.0 1.32 (1.15‐1.52) 1.33 (1.15‐1.54)
Latino American 276 697,674.8 0.95 (0.81‐1.12) 0.90 (0.76‐1.07)
Family history of pancreatic cancer
No 1,478 3,060,983.6 1 (ref) 1 (ref)
Yes 54 53,854.1 1.93 (1.47‐2.53) 1.97 (1.50‐2.58)
Diabetes
No 1,316 2,808,732.7 1 (ref) 1 (ref)
Yes 216 306,105.0 1.37 (1.18‐1.58) 1.32 (1.14‐1.54)
Body mass index (kg/m2)
<25 625 1,299,492.5 1 (ref) 1 (ref)
25‐30 599 1,203,354.1 1.09 (0.97‐1.23) 1.09 (0.97‐1.23)
≥30 308 611,991.0 1.27 (1.10‐1.47) 1.25 (1.08‐1.46)
ptrend c     <0.01 0.01
Smoking status, with pack‐year information
Never 679 1,459,583.7 1 (ref) 1 (ref)
Past <20 pack‐years 414 908,445.2 1.00 (0.88‐1.13) 0.99 (0.87‐1.12)
Past ≥20 pack‐years 152 279,328.2 1.02 (0.85‐1.22) 0.97 (0.81‐1.17)
Current <20 pack‐years 140 264,554.3 1.44 (1.20‐1.74) 1.43 (1.19‐1.73)
Current ≥20 pack‐years 147 202,926.3 1.77 (1.47‐2.13) 1.76 (1.46‐2.12)
ptrend c     <0.0001 <0.0001
Alcohol use (g/day)
None 820 1,570,115.6 1 (ref) 1 (ref)
<24 544 1,197,773.7 0.97 (0.87‐1.09) 0.98 (0.88‐1.11)
24‐48 108 221,918.6 1.03 (0.83‐1.26) 1.00 (0.81‐1.24)
>48 60 125,029.8 0.99 (0.76‐1.30) 0.95 (0.73‐1.25)
ptrend c     0.94 0.66
Red meat intake (g/kcal/day)
Q1 (0‐14.1) 347 790,241.8 1 (ref) 1 (ref)
Q2 (14.1‐23.9) 427 778,626.9 1.26 (1.10‐1.46) 1.23 (1.06‐1.42)
Q3 (23.9‐35.2) 384 779,380.7 1.20 (1.03‐1.38) 1.13 (0.97‐1.31)
Q4 (35.2‐216.5) 374 766,588.4 1.29 (1.11‐1.49) 1.17 (1.00‐1.36)
ptrend c     <0.01 0.11
a

Age and sex as strata variables, race as covariate.

b

Age and sex as strata variables, race, smoking with pack‐year information, alcohol use, BMI, family history of pancreatic cancer, diabetes, and red meat intake as covariates.

c

From a model treating exposure as continuous variable coded as consecutive numbers (eg, 1, 2, 3).

We observed higher pancreatic cancer risk associated with family history of pancreatic cancer (RR 1.97, 95% CI 1.50‐2.58), diabetes (RR 1.32, 95% CI 1.14‐1.54), BMI ≥30 kg/m2 (RR 1.25, 95% CI 1.08‐1.46), current smoking (<20 pack‐years: RR 1.43, 95% CI 1.19‐1.73; ≥20 pack‐years: RR 1.76, 95% CI 1.46‐2.12), and red meat (Q4 vs Q1: RR 1.17, 95% CI 1.00‐1.36) (Table 3).

While there was no heterogeneity across race/ethnicity, the associations of these risk factors appeared stronger for particular subgroups (Table 4). The association between first‐degree family history of pancreatic cancer and risk of pancreatic cancer was greatest for Japanese Americans (RR 2.43, 95% CI 1.69‐3.50) and African Americans (RR 2.18, 95% CI 1.07‐4.41), while diabetes had the largest influence in Native Hawaiians (RR 2.01, 95% CI 1.30‐3.12). BMI ≥30 kg/m2 had the greatest association for Japanese Americans (RR 1.79, 95% CI 1.30‐2.45), followed by Latino Americans (RR 1.36, 95% CI 0.96‐1.92), and Native Hawaiians (RR 1.28, 95% CI 0.79‐2.08). Current smoking status had the strongest association with pancreatic cancer among Japanese Americans (RR 1.92 95% CI 1.48‐2.49) and African Americans (RR 1.67, 95% CI 1.22‐2.31). Likewise, greater pack‐years of smoking had a larger impact for Japanese Americans (current smoking ≥20 pack‐years: RR 2.28, 95% CI 1.67‐3.12) and African Americans (current smoking ≥20 pack‐years: RR 1.85, 95% CI 1.17‐2.90). Red meat had the strongest influence in African Americans (highest vs lowest quartile: RR 1.48, 95% CI 1.03‐2.14).

Table 4.

Association between risk factors and pancreatic cancer risk, by race/ethnicity

Risk factor European American African American Native Hawaiian Japanese American Latino American P b
Cases RR (95% CI)a Cases RR (95% CI)a Cases RR (95% CI)a Cases RR (95% CI)a Cases RR (95% CI)a
Family history of pancreatic cancer
No 299 1 (ref) 269 1 (ref) 126 1 (ref) 514 1 (ref) 270 1 (ref) 0.48
Yes 7 1.34 (0.63‐2.85) 8 2.18 (1.07‐4.41) 2 0.93 (0.23‐3.79) 31 2.43 (1.69‐3.50) 6 1.56 (0.69‐3.52)  
Diabetes
No 284 1 (ref) 231 1 (ref) 100 1 (ref) 482 1 (ref) 219 1 (ref) 0.33
Yes 22 1.40 (0.90‐2.19) 46 1.19 (0.85‐1.65) 28 2.01 (1.30‐3.12) 63 1.10 (0.84‐1.44) 57 1.54 (1.14‐2.09)  
Body mass index (kg/m2)
<25 141 1 (ref) 74 1 (ref) 31 1 (ref) 314 1 (ref) 65 1 (ref) 0.37
25‐30 110 0.91 (0.70‐1.18) 116 0.95 (0.71‐1.28) 52 1.20 (0.76‐1.90) 183 1.17 (0.97‐1.42) 138 1.24 (0.92‐1.68)  
≥30 55 1.06 (0.76‐1.46) 87 0.94 (0.68‐1.29) 45 1.28 (0.79‐2.08) 48 1.79 (1.30‐2.45) 73 1.36 (0.96‐1.92)  
ptrend d   0.89   0.72   0.42   <0.01   0.11  
Smoking statusc
Never 125 1 (ref) 105 1 (ref) 53 1 (ref) 260 1 (ref) 136 1 (ref) 0.71
Past 124 0.85 (0.66‐1.10) 101 1.08 (0.81‐1.43) 44 0.88 (0.58‐1.33) 199 1.04 (0.85‐1.28) 98 0.93 (0.70‐1.22)  
Current 57 1.39 (1.00‐1.92) 71 1.67 (1.22‐2.31) 31 1.52 (0.95‐2.43) 86 1.92 (1.48‐2.49) 42 1.22 (0.84‐1.75)  
Smoking status, with pack‐year informationc
Never 125 1 (ref) 105 1 (ref) 53 1 (ref) 260 1 (ref) 136 1 (ref) 0.71
Past <20 pack‐years 85 0.90 (0.68‐1.19) 72 0.98 (0.72‐1.33) 35 0.98 (0.63‐1.51) 136 1.04 (0.83‐1.30) 86 0.96 (0.72‐1.27)  
Past ≥20 pack‐years 39 0.76 (0.52‐1.10) 29 1.56 (1.01‐2.40) 9 0.62 (0.30‐1.29) 63 1.09 (0.81‐1.48) 12 0.75 (0.41‐1.38)  
Current <20 pack‐years 19 1.29 (0.79‐2.11) 46 1.60 (1.11‐2.31) 15 1.53 (0.84‐2.78) 31 1.53 (1.05‐2.24) 29 1.18 (0.77‐1.78)  
Current ≥20 pack‐years 38 1.43 (0.98‐2.09) 25 1.85 (1.17‐2.90) 16 1.51 (0.84‐2.71) 55 2.28 (1.67‐3.12) 13 1.32 (0.72‐2.42)  
ptrend d   0.14   <0.001   0.18   <0.0001   0.52  
Alcohol use (g/day)
None 103 1 (ref) 170 1 (ref) 67 1 (ref) 347 1 (ref) 133 1 (ref) 0.11
≤24 141 1.02 (0.79‐1.32) 90 0.82 (0.63‐1.07) 44 1.11 (0.75‐1.66) 142 0.91 (0.74‐1.12) 127 1.20 (0.93‐1.55)  
24‐48 34 0.92 (0.62‐1.37) 12 0.75 (0.41‐1.37) 10 1.18 (0.59‐2.37) 41 1.31 (0.93‐1.84) 11 0.70 (0.36‐1.35)  
>48 28 1.29 (0.84‐1.99) 5 0.46 (0.19‐1.15) 7 1.54 (0.68‐3.50) 15 1.01 (0.59‐1.72) 5 0.51 (0.20‐1.25)  
ptrend d   0.65   0.04   0.35   0.72   0.44  
Red meat intake (g/kcal/day)
Q1 (0‐14.1) 88 1 (ref) 54 1 (ref) 27 1 (ref) 130 1 (ref) 48 1 (ref) 0.30
Q2 (14.1‐23.9) 90 1.26 (0.94‐1.70) 66 1.40 (0.97‐2.02) 31 0.80 (0.47‐1.35) 174 1.25 (0.99‐1.57) 66 1.19 (0.82‐1.73)  
Q3 (23.9‐35.2) 66 1.08 (0.78‐1.50) 82 1.78 (1.25‐2.52) 36 0.81 (0.49‐1.36) 135 1.00 (0.78‐1.28) 65 1.10 (0.75‐1.61)  
Q4 (35.2‐216.5) 62 1.22 (0.87‐1.72) 75 1.48 (1.03‐2.14) 34 0.66 (0.39‐1.13) 106 1.03 (0.78‐1.34) 97 1.38 (0.96‐1.98)  
ptrend d   0.32   0.02   0.16   0.71   0.08  
a

Age and sex as strata variables, race, smoking status with pack‐year information, alcohol use, BMI, family history of pancreatic cancer, diabetes, and red meat intake as covariates.

b

P values for heterogeneity across race.

c

Smoking status and smoking status with pack‐year information assessed in separate models.

d

From a model treating exposure as continuous variable coded as consecutive numbers (eg, 1, 2, 3).

From the PAF calculations, diabetes, BMI ≥25, current smoking, and red meat intake altogether accounted for one fifth of pancreatic cancer cases (PAF 21.57, 95% CI 12.37‐29.81). Across racial/ethnic groups, this combination of risk factors explained similar proportions of cases in Latino Americans (32.21, 95% CI 5.94‐51.15), African Americans (29.48, 95% CI 3.73‐48.34), and Japanese Americans (19.75, 95% CI 5.22‐32.06), but lower proportions of cases in European Americans (9.00, 95% CI −12.20 to 26.19) and Native Hawaiians (7.10, 95% CI −46.51 to 41.10). When evaluating the individual risk factors, about 8% of cases could be attributed to BMI ≥25 (PAF 7.59, 95% CI 1.41‐13.37) and 3% to BMI ≥30 (PAF 3.36, 95% CI 0.55‐6.09). These estimates were similar for Japanese Americans (BMI ≥25: PAF 8.63, 95% CI 1.59‐15.16; BMI ≥30 PAF 3.53, 95% CI 0.97‐6.02), but were not statistically significant for the other race/ethnicity subgroups (data not shown). In addition, current smoking explained approximately 4% of cases for the whole cohort (PAF 4.19, 95% CI 1.67‐6.64) and about 6% of cases among Japanese Americans (6.29, 95% CI 2.64‐9.80). However, the PAFs for current smoking were not significant for European Americans (1.46, 95% CI −4.56 to 7.13), African Americans (6.56, 95% CI −0.84 to 13.42), Native Hawaiians (3.37, 95% CI −7.49 to 13.14), or Latino Americans (1.00, 95% CI −4.44 to 6.16). For red meat, about 10% of the cases could be prevented (PAF 9.97, 95% CI 0.99‐18.15) if those in the upper three quartiles of red meat consumption reduced their intake to the first quartile. This decrease was over doubled among African Americans (PAF 26.40, 95% CI 5.73‐42.54), but was not statistically significant for the other populations. There was no decrease in pancreatic cancer burden associated with a modification in diabetes status for the entire cohort (PAF 1.06, 95% CI −1.01 to 3.10) or within any subgroups.

4. DISCUSSION

In this study, we evaluated differences in pancreatic cancer incidence and risk factor associations across five racial/ethnic groups in the MEC. We observed higher rates of pancreatic cancer among African Americans, Native Americans, and Japanese Americans, but no difference for Latino Americans, compared to European Americans. While these disparities did not seem to be fully explained by the distribution and effects of risk factors across race/ethnicity, a substantial fraction of pancreatic cancers in our cohort (20%) could be attributed to smoking, adiposity, and red meat intake.

African Americans have had historically higher rates of pancreatic cancer incidence compared to whites.14 While risk factors such as obesity, diabetes, and smoking are more prevalent among African Americans, past research has suggested that they do not fully explain the differences in pancreatic cancer incidence.15, 16 Our findings provide additional support for this disparity, as African Americans had a 20% greater risk of pancreatic cancer compared to European Americans even after adjusting for known risk factors. Thus, other factors not reflected in our analysis may instead account for these differences in incidence. In particular, current evidence has suggested that African Americans may perhaps have higher exposure to carcinogens compared to European Americans. This is supported by research suggesting that African Americans are slower metabolizers of cigarette smoke toxins17 and are more likely to have the risky rapid phenotype of the N‐acetyltransferase‐1 enzyme,18 which promotes the bioactivation of arylamine carcinogens.19 Smoking and dietary preferences among this population may also contribute to elevated carcinogen exposure. African Americans tend to smoke menthol cigarettes,17, 20 which facilitate deeper inhalation and penetration of harmful tobacco products,21 and consume higher amounts of well‐done and pan‐fried meats,18, 22 which have increased levels of heterocyclic amines and polycyclic aromatic hydrocarbons.23 These issues could thus potentially explain why the impact of smoking and red meat were stronger for African Americans in our analyses. In addition, higher rates of pancreatic cancer among African Americans may be attributed to differences in genetic susceptibility. As there is currently a lack of studies examining genetics and pancreatic cancer in this population, our results may provide an indication of which specific genetic markers to investigate in future studies.

Pancreatic cancer incidence rates have also been consistently elevated among Native Hawaiians according to the Hawaii Tumor Registry and other SEER registries.24, 25 In our cohort, Native Hawaiians had the greatest disparity among all race/ethnicity groups, with nearly double the age‐adjusted incidence rate and about a 60% greater relative risk of pancreatic cancer compared to European Americans after risk factor adjustment. This difference in incidence can perhaps be explained by race‐specific variations in the susceptibility and severity of diabetes, which was a strong independent risk factor among Native Hawaiians in our analysis. Literature has shown that there is a disproportionate burden of diabetes among Native Hawaiians, as both the prevalence and risk of diabetes is much higher for Native Hawaiians compared to European Americans.26, 27, 28 There is also evidence suggesting that diabetes may be more critical and advanced in this population. Native Hawaiians are more frequently hospitalized for diabetes29 and have a greater likelihood of experiencing diabetes‐related complications and mortality.26, 30 In addition, Native Hawaiians are more likely to have poorer glycemic control and elevated blood glucose levels,31, 32 which have been observed to be associated with pancreatic cancer.33 Future studies investigating diabetes severity and pancreatic cancer across race/ethnicity groups would be valuable in understanding this increased incidence among Native Hawaiians.

We found that Japanese Americans had both a higher incidence rate and relative risk for pancreatic cancer compared to European Americans. While not previously highlighted, recent incidence data (2009‐2013) from the Hawaii Tumor Registry showed that Japanese individuals had greater age‐adjusted incidence rates compared to European Americans.24 We also observed that the relative risk for Japanese Americans remained practically unchanged between our minimally and fully adjusted models, indicating that our covariates did not explain much of the disparity. However, the fact that family history of pancreatic cancer was a stronger risk factor among Japanese Americans than among European Americans suggests that genetics may play a more substantial role in defining risk between race/ethnicity groups. This hypothesis is supported by a previous genome‐wide association study (GWAS) in Japanese individuals, which identified three pancreatic cancer susceptibility loci that were not observed to be associated with risk in prior GWAS studies of individuals of European ancestry.34, 35, 36 A recent GWAS meta‐analysis of three Japanese studies further found a genetic risk marker in GP2 that is also distinct to this population.37 In addition, non‐O blood alleles, which are associated with pancreatic cancer,38 appear to be more prevalent in Japanese individuals compared to Europeans.39

Our analysis did not detect any difference in pancreatic cancer incidence and risk between Latino Americans and European Americans. Additionally, our race/ethnicity‐stratified models showed that the patterns of associations for each risk factor and pancreatic cancer were similar between European and Latino Americans. Data from SEER and the CDC's National Program of Cancer Registries have reported similar age‐standardized incidence rates between Hispanic and white females, but slightly lower rates for Hispanic men compared to white men.40, 41 It is possible that the decreased rates for Hispanic males may be attributed to the lower prevalence of smoking in this population.42

To our knowledge, this is the first study to calculate PAFs for pancreatic cancer risk factors across race/ethnicity using a formula that accounts for the competing risk of death. Our PAF estimates for current smoking (1%‐7%) are lower than the PAFs for smoking reported in two prior studies (15%‐42%) examining pancreatic cancer risk factors in whites and blacks.6, 16 However, it may be difficult to make direct comparisons with these studies because the authors used formulas that did not consider follow‐up time or mortality and did not calculate separate PAFs for current smoking alone. In addition, PAF calculations that ignore mortality tend to overestimate the PAF when the follow‐up period is long and the risk factor in question is strongly associated with mortality.43 As the average follow‐up time was 16.9 years and smoking had a greater influence on mortality than pancreatic cancer in our cohort, using a formula that addressed censoring due to death was more appropriate and provided a more accurate PAF estimation.

The strengths of our study include the prospective design and large, ethnically diverse population. This permitted us to evaluate disparities in incidence and the influence of risk factors across several race/ethnicity groups, particularly minority populations that have been understudied. Furthermore, calculating PAFs using a formula designed specifically for cohort studies that controlled for competing risk of death and other risk factors provided a more unbiased PAF estimate compared to previous studies. However, as a number of risk factors were assessed by self‐report, the accuracy of some data elements may have been influenced by social desirability bias. Since the baseline questionnaire was administered prior to case identification, we expect any misclassification to be nondifferential and bias our results toward the null. In addition, we used sociocultural categories of race/ethnicity, which does not fully capture all variation in risk associated with genetic ancestry. Incorporating genetic data, as well as biomarker or imaging information to assess pancreatic fat (an emerging risk factor44), could have perhaps further accounted for some of the disparities between populations.

This study provided a comprehensive assessment of the incidence and known risk factors for pancreatic cancer across multiple racial/ethnic populations. Our findings suggest that the racial disparities in pancreatic cancer incidence are not fully explained by the interethnic differences in the distribution and effects of these mainly environmental risk factors. Residual risk in pancreatic cancer incidence may in fact be explained by other genetic and biological factors. Thus, future studies should consider more detailed evaluations that incorporate both behavioral and genetic data to further elucidate these discrepancies between race/ethnicity groups.

ACKNOWLEDGMENTS

This work was supported by the National Cancer Institute at the National Institutes of Health (RO1CA209798 to VWS and UO1CA164973 to LLM). V. Wendy Setiawan is supported by an American Cancer Society Research Scholar Grant (RSG‐16–250‐01‐CPHPS). Brian Z. Huang is supported by the T32 Training Grant in Cancer Epidemiology (T32CA009142) at UCLA.

Huang BZ, Stram DO, Le Marchand L, et al. Interethnic differences in pancreatic cancer incidence and risk factors: The Multiethnic Cohort. Cancer Med. 2019;8:3592–3603. 10.1002/cam4.2209

DATA AVAILABILITY STATEMENT

Data available on request from the authors.

REFERENCES

  • 1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68:7‐30. [DOI] [PubMed] [Google Scholar]
  • 2. Rahib L, Smith BD, Aizenberg R, Rosenzweig AB, Fleshman JM, Matrisian LM. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res. 2014;74:2913‐2921. [DOI] [PubMed] [Google Scholar]
  • 3. Cervantes A, Waymouth EK, Petrov MS, et al. African‐Americans and indigenous peoples have increased burden of diseases of the exocrine pancreas: a systematic review and meta‐analysis. Cancer Causes Control. 2018;21:853‐861. [DOI] [PubMed] [Google Scholar]
  • 4. Maisonneuve P, Lowenfels AB. Epidemiology of pancreatic cancer: an update. Dig Dis. 2010;28:645‐656. [DOI] [PubMed] [Google Scholar]
  • 5. Yadav D, Lowenfels AB. The epidemiology of pancreatitis and pancreatic cancer. Gastroenterology. 2013;144:1252‐1261. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6. Silverman DT, Hoover RN, Brown LM, et al. Why do Black Americans have a higher risk of pancreatic cancer than White Americans? Epidemiology. 2003;14:45‐54. [DOI] [PubMed] [Google Scholar]
  • 7. Chang KJ, Parasher G, Christie C, Largent J, Anton‐Culver H. Risk of pancreatic adenocarcinoma: disparity between African Americans and other race/ethnic groups. Cancer. 2005;103:349‐357. [DOI] [PubMed] [Google Scholar]
  • 8. Zhou J, Enewold L, Stojadinovic A, et al. Incidence rates of exocrine and endocrine pancreatic cancers in the United States. Cancer Causes Control. 2010;21:853‐861. [DOI] [PubMed] [Google Scholar]
  • 9. Kolonel LN, Henderson BE, Hankin JH, et al. A multiethnic cohort in Hawaii and Los Angeles: baseline characteristics. Am J Epidemiol. 2000;151:346‐357. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10. Stram DO, Hankin JH, Wilkens LR, et al. Calibration of the dietary questionnaire for a multiethnic cohort in Hawaii and Los Angeles. Am J Epidemiol. 2000;151:358‐370. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11. Haiman CA, Stram DO, Wilkens LR, et al. Ethnic and racial differences in the smoking‐related risk of lung cancer. N Engl J Med. 2006;354:333‐342. [DOI] [PubMed] [Google Scholar]
  • 12. Laaksonen Virtala E, Knekt P, Oja H, Härkänen TM. SAS macros for calculation of population attributable fraction in a cohort study design. J Stat Softw. 2011;43:1‐25. https://www.jstatsoft.org/v043/i07. Accessed April 25, 2018. [Google Scholar]
  • 13. Bradburn MJ, Clark TG, Love SB, Altman DG. Survival analysis part III: multivariate data analysis – choosing a model and assessing its adequacy and fit. Br J Cancer. 2003;89:605‐611. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14. Zhang J, Dhakal I, Yan H, Phillips M, Kesteloot H. Trends in pancreatic cancer incidence in nine SEER cancer registries, 1973–2002. Ann Oncol Off J Eur Soc Med Oncol. 2007;18:1268‐1279. [DOI] [PubMed] [Google Scholar]
  • 15. Khawja SN, Mohammed S, Silberfein EJ, Musher BL, Fisher WE, II Van Buren G, . Pancreatic cancer disparities in African Americans. Pancreas. 2015;44:522‐527. [DOI] [PubMed] [Google Scholar]
  • 16. Arnold LD, Patel AV, Yan Y, et al. Are racial disparities in pancreatic cancer explained by smoking and overweight/obesity? Cancer Epidemiol Biomarkers Prev. 2009;18:2397‐2405. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17. Muscat JE, Djordjevic MV, Colosimo S, Stellman SD, Richie JPJ. Racial differences in exposure and glucuronidation of the tobacco‐specific carcinogen 4‐(methylnitrosamino)‐1‐(3‐pyridyl)‐1‐butanone (NNK). Cancer. 2005;103:1420‐1426. [DOI] [PubMed] [Google Scholar]
  • 18. Sharma S, Cao X, Wilkens LR, et al. Well‐done meat consumption, NAT1 and NAT2 acetylator genotypes and prostate cancer risk: the multiethnic cohort study. Cancer Epidemiol Biomarkers Prev. 2010;19:1866‐1870. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19. Wormhoudt LW, Commandeur JN, Vermeulen NP. Genetic polymorphisms of human N‐acetyltransferase, cytochrome P450, glutathione‐S‐transferase, and epoxide hydrolase enzymes: relevance to xenobiotic metabolism and toxicity. Crit Rev Toxicol. 1999;29:59‐124. [DOI] [PubMed] [Google Scholar]
  • 20. Jones MR, Apelberg BJ, Tellez‐Plaza M, Samet JM, Navas‐Acien A. Menthol cigarettes, race/ethnicity, and biomarkers of tobacco use in U.S. adults: the 1999–2010 National Health and Nutrition Examination Survey (NHANES). Cancer Epidemiol Biomarkers Prev. 2013;22:224‐232. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21. Squier CA, Mantz MJ, Wertz PW. Effect of menthol on the penetration of tobacco carcinogens and nicotine across porcine oral mucosa ex vivo. Nicotine Tob Res. 2010;12:763‐767. [DOI] [PubMed] [Google Scholar]
  • 22. John EM, Stern MC, Sinha R, Koo J. Meat consumption, cooking practices, meat mutagens, and risk of prostate cancer. Nutr Cancer. 2011;63:525‐537. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23. Sinha R, Rothman N, Salmon CP, et al. Heterocyclic amine content in beef cooked by different methods to varying degrees of doneness and gravy made from meat drippings. Food Chem Toxicol. 1998;36:279‐287. [DOI] [PubMed] [Google Scholar]
  • 24. Hawaii Tumor Registry, University of Hawaii Cancer Center . Hawai’i Cancer at a Glance. 2013.
  • 25. Liu L, Noone A‐M, Gomez SL, et al. Cancer incidence trends among native Hawaiians and other Pacific Islanders in the United States, 1990–2008. J Natl Cancer Inst. 2013;105:1086‐1095. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26. King GL, McNeely MJ, Thorpe LE, et al. Understanding and addressing unique needs of diabetes in Asian Americans, native Hawaiians, and Pacific Islanders. Diabetes Care. 2012;35:1181‐1188. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27. Karter AJ, Schillinger D, Adams AS, et al. Elevated rates of diabetes in Pacific Islanders and Asian subgroups: the Diabetes Study of Northern California (DISTANCE). Diabetes Care. 2013;36:574‐579. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28. Maskarinec G, Jacobs S, Morimoto Y, Chock M, Grandinetti A, Kolonel LN. Disparity in diabetes risk across native Hawaiians and different Asian groups: the multiethnic cohort. Asia‐Pacific J public Heal. 2015;27:375‐384. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29. Sentell TL, Cheng Y, Saito E, et al. The burden of diagnosed and undiagnosed diabetes in native Hawaiian and Asian American hospitalized patients. J Clin Transl Endocrinol. 2015;2:115‐124. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30. Golden SH, Brown A, Cauley JA, et al. Health disparities in endocrine disorders: biological, clinical, and nonclinical factors–an endocrine society scientific statement. J Clin Endocrinol Metab. 2012;97:E1579‐E1639. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31. Lee R, Onopa J, Mau MK, Seto TB. Diabetes care in a predominantly native Hawaiian and Pacific Islander outpatient population. Hawaii Med J. 2010;69:28‐30. [PMC free article] [PubMed] [Google Scholar]
  • 32. Grandinetti A, Kaholokula JK, Chang HK, et al. Relationship between plasma glucose concentrations and native Hawaiian ancestry: the Native Hawaiian Health Research Project. Int J Obes Relat Metab Disord. 2002;26:778‐782. [DOI] [PubMed] [Google Scholar]
  • 33. Liao WC, Tu YK, Wu MS, Lin JT, Wang HP, Chien KL. Blood glucose concentration and risk of pancreatic cancer: systematic review and dose‐response meta‐analysis. BMJ. 2015;350:g7371. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34. Amundadottir L, Kraft P, Stolzenberg‐Solomon RZ, et al. Genome‐wide association study identifies variants in the ABO locus associated with susceptibility to pancreatic cancer. Nat Genet. 2009;41:986‐990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35. Petersen GM, Amundadottir L, Fuchs CS, et al. A genome‐wide association study identifies pancreatic cancer susceptibility loci on chromosomes 13q22.1, 1q32.1 and 5p15.33. Nat Genet. 2010;42:224‐228. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36. Low S‐K, Kuchiba A, Zembutsu H, et al. Genome‐Wide association study of pancreatic cancer in Japanese population. PLoS ONE. 2010;5:e11824 10.1371/journal.pone.0011824 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37. Lin Y, Nakatochi M, Ito H, et al. Genome‐wide association meta‐analysis identifies novel GP2 gene risk variants for pancreatic cancer in the Japanese population. bioRxiv. 2018;498659 http://biorxiv.org/content/early/2018/12/19/498659. Accessed March 27, 2019. [Google Scholar]
  • 38. Wolpin BM, Kraft P, Gross M, et al. Pancreatic cancer risk and ABO blood group alleles: results from the pancreatic cancer cohort consortium. Cancer Res. 2010;70:1015‐1023. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39. Risch HA, Lu L, Wang J, et al. ABO blood group and risk of pancreatic cancer: a study in Shanghai and meta‐analysis. Am J Epidemiol. 2013;177:1326‐1337. 10.1093/aje/kws458 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40. Cronin KA, Lake AJ, Scott S, et al. Annual report to the nation on the status of cancer, part I: national cancer statistics. Cancer. 2018;124:2785‐2800. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41. Gordon‐Dseagu VL, Devesa SS, Goggins M, Stolzenberg‐Solomon R. Pancreatic cancer incidence trends: evidence from the Surveillance, Epidemiology and End Results (SEER) population‐based data. Int J Epidemiol. 2018;47:427‐439. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42. Jamal A, King BA, Neff LJ, Whitmill J, Babb SD, Graffunder CM. Current cigarette smoking among adults – United States, 2005–2015. MMWR Morb Mortal Wkly Rep. 2016;65:1205‐1211. [DOI] [PubMed] [Google Scholar]
  • 43. Laaksonen MA, Harkanen T, Knekt P, Virtala E, Oja H. Estimation of population attributable fraction (PAF) for disease occurrence in a cohort study design. Stat Med. 2010;29:860‐874. [DOI] [PubMed] [Google Scholar]
  • 44. Majumder S, Philip NA, Takahashi N, Levy MJ, Singh VP, Chari ST. Fatty pancreas: should we be concerned? Pancreas. 2017;46:1251‐1258. [DOI] [PMC free article] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Data Availability Statement

Data available on request from the authors.


Articles from Cancer Medicine are provided here courtesy of Wiley

RESOURCES